News - CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
GSK goes all-in on CureVac’s mRNA vaccines | pharmaphorum
4 days ago · GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and...
Why CureVac (CVAC) Stock Is Rising - Benzinga
4 days ago · In the case of CureVac, which is trading at $4.07 as of publishing time, $100 would buy you 24.57 shares of stock. If you're looking to bet against a company, the process is more complex.
BioNTech wins round in CureVac mRNA patent dispute
5 days ago · CureVac – which is developing mRNA-based vaccines for COVID-19 and influenza with GSK – filed suit in the Düsseldorf Regional Court last year, claiming infringement of five patents. A judgment on...
CureVac gains $430M GSK vaccine contract, loses 30% of staff
Jul 3, 2024 · GSK is paying 400 million euros ($430 million) upfront for full rights to CureVac’s vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a...
CureVac cuts jobs, licenses out vaccines to GSK
Jul 3, 2024 · CureVac, a specialist in messenger RNA-based therapies, disclosed Wednesday plans to lay off 30% of its workforce as part of a “significant strategic restructuring” that will direct the company’s resources toward “high-value” projects.
CureVac Announces Positive Phase 2 Interim Data from COVID-19 …
Jan 5, 2024 · Results from the formal interim analysis showed that both vaccine candidates using CureVac's proprietary second-generation mRNA backbone produced meaningful immune responses and favorable...
CureVac-News: Aktuelle Nachrichten zur Curevac AG - Handelsblatt
Lesen Sie hier aktuelle News und die neuesten Nachrichten von heute zum Biotechunternehmen CureVac. Insgesamt flossen 2024 fast zwei Milliarden Euro neues Kapital an deutsche …
CureVac Announces Positive Data on Joint COVID-19 and Flu …
Jan 6, 2023 · The preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages...
GSK and CureVac to Restructure Collaboration into New Licensing ...
Jul 3, 2024 · GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.